Old variables, new value: A refined IPI for DLBCL

摘要

In this issue of Blood, Zhou and colleagues present a refined prognostic index for patients with de novo diffuse large B-cell lymphoma (DLBCL), addressing the need for a tool that can better separate risk groups in the rituximab era.